This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: July 23, 2012
Last updated: November 1, 2016
Last verified: November 2016
This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.

Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION II Study)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients on RoActemra/Actemra at 6 months after initiating treatment [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Frequency of withdrawal (according to reasons) [ Time Frame: 12 months ]
  • Frequency of dose modifications [ Time Frame: 12 months ]
  • Change in disease activity (DAS28) [ Time Frame: from baseline to Month 6 or withdrawal, whichever comes first ]

Enrollment: 183
Study Start Date: May 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Rheumatoid arthritis patients suitable for treatment with RoActemra/Actemra according to SPC

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline
  • RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing
  • Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis

Exclusion Criteria:

  • Rheumatic autoimmune disease other than RA
  • Participation in interventional clinical trials during the observational period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01649817

Agia Paraskevi, Greece, 15342
Agios Dimitrios, Greece, 17343
Argiroupoli, Greece, 16452
Athens, Greece, 11473
Athens, Greece, 11521
Athens, Greece, 155 62
Athens, Greece
Chalandri, Greece
Chania, Greece, 73134
Eleusina, Greece, 19200
Herakleio, Greece, 71307
Ioannina, Greece, 455 00
Kifisia, Greece
Korinthos, Greece, 20100
Peristeri, Greece, 12934
Peuki, Greece, 15121
Rethymno, Greece, 74100
Serres, Greece, 62122
Thessaloniki, Greece, 54621
Thessaloniki, Greece, 54622
Thessaloniki, Greece, 54623
Thessaloniki, Greece, 54624
Thessaloniki, Greece
Volos, Greece, 38221
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01649817     History of Changes
Other Study ID Numbers: ML28258
Study First Received: July 23, 2012
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017